Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 592

1.

Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine.

Mendoza-Baumgart MI, Tulunay OE, Hecht SS, Zhang Y, Murphy S, Le C, Jensen J, Hatsukami DK.

Nicotine Tob Res. 2007 Dec;9(12):1309-23.

PMID:
18058349
2.

Clinical laboratory evaluation of potential reduced exposure products for smokers.

Breland AB, Kleykamp BA, Eissenberg T.

Nicotine Tob Res. 2006 Dec;8(6):727-38.

PMID:
17132520
3.
4.

Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum.

Lunell E, Curvall M.

Nicotine Tob Res. 2011 Jul;13(7):573-8. doi: 10.1093/ntr/ntr044. Epub 2011 Mar 31.

PMID:
21454913
5.

Smokeless tobacco use: harm reduction or induction approach?

Hatsukami DK, Lemmonds C, Tomar SL.

Prev Med. 2004 Mar;38(3):309-17. Review.

PMID:
14766113
6.

Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker?

Fagerström KO, Tejding R, Westin A, Lunell E.

Tob Control. 1997 Winter;6(4):311-6.

7.

Comparative efficacy of rapid-release nicotine gum versus nicotine polacrilex gum in relieving smoking cue-provoked craving.

Niaura R, Sayette M, Shiffman S, Glover ED, Nides M, Shelanski M, Shadel W, Koslo R, Robbins B, Sorrentino J.

Addiction. 2005 Nov;100(11):1720-30.

PMID:
16277632
8.

Pharmacokinetics of a nicotine polacrilex lozenge.

Choi JH, Dresler CM, Norton MR, Strahs KR.

Nicotine Tob Res. 2003 Oct;5(5):635-44.

PMID:
14577980
9.

[New therapeutic options for smoking cessation. Nicotine polacrilex tablets for tobacco cessation].

Noé S.

Med Monatsschr Pharm. 2003 Dec;26(12):418-22. Review. German. No abstract available.

PMID:
14699778
10.

Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler.

Hajek P, West R, Foulds J, Nilsson F, Burrows S, Meadow A.

Arch Intern Med. 1999 Sep 27;159(17):2033-8.

PMID:
10510989
11.

Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge.

Kotlyar M, Mendoza-Baumgart MI, Li ZZ, Pentel PR, Barnett BC, Feuer RM, Smith EA, Hatsukami DK.

Tob Control. 2007 Apr;16(2):138-42.

12.
13.
14.
15.

Levels of cotinine associated with long-term ad-libitum nicotine polacrilex use in a clinical trial.

Murray RP, Nides MA, Istvan JA, Daniels K.

Addict Behav. 1998 Jul-Aug;23(4):529-35.

PMID:
9698981
16.

Randomised clinical trial of snus versus medicinal nicotine among smokers interested in product switching.

Hatsukami DK, Severson H, Anderson A, Vogel RI, Jensen J, Broadbent B, Murphy SE, Carmella S, Hecht SS.

Tob Control. 2016 May;25(3):267-74. doi: 10.1136/tobaccocontrol-2014-052080. Epub 2015 May 19.

17.

Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette.

Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.

Cancer Epidemiol Biomarkers Prev. 2007 Nov;16(11):2479-85.

18.

Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products.

Hatsukami DK, Lemmonds C, Zhang Y, Murphy SE, Le C, Carmella SG, Hecht SS.

J Natl Cancer Inst. 2004 Jun 2;96(11):844-52.

PMID:
15173268
19.

Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study.

Kotlyar M, Hertsgaard LA, Lindgren BR, Jensen JA, Carmella SG, Stepanov I, Murphy SE, Hecht SS, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):91-100. doi: 10.1158/1055-9965.EPI-10-0349. Epub 2010 Nov 10. Erratum in: Cancer Epidemiol Biomarkers Prev. 2011 May;20(5):1048.

20.

Changing smokeless tobacco products new tobacco-delivery systems.

Hatsukami DK, Ebbert JO, Feuer RM, Stepanov I, Hecht SS.

Am J Prev Med. 2007 Dec;33(6 Suppl):S368-78. Review.

PMID:
18021912

Supplemental Content

Support Center